Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14957312 | 1.00 | CYP2D6 (0.54) | CYP2D6CYP3A4TSHRLTA4HCYP1A2 | |
| SCHEMBL14957149 | 1.00 | CYP2D6 (0.54) | CYP2D6CYP3A4TSHRLTA4HCYP1A2 | |
| Potassium Ion SCHEMBL30502359 | 0.87 | CYP2D6 (0.51) | CYP2D6CYP3A4TSHRCYP1A2OPRL1 | |
| SCHEMBL18929838 | 0.85 | KDM4E (0.56) | OPRL1CHRM2HPGD | |
| SCHEMBL14962729 | 0.84 | CYP2D6 (0.53) | CYP2D6CYP3A4TSHRCYP1A2CHRM2 | |
| SCHEMBL14677254 | 0.84 | CYP2D6 (0.53) | CYP2D6CYP3A4TSHRCYP1A2CHRM2 | |
| SCHEMBL14962728 | 0.84 | CYP2D6 (0.53) | CYP2D6CYP3A4TSHRCYP1A2CHRM2 | |
| SCHEMBL2146325 | 0.81 | CYP2D6 (0.49) | CYP2D6CYP3A4TSHRCYP1A2CYP2C9 | |
| SCHEMBL11544321 | 0.81 | OPRL1 (0.57) | CYP2D6CYP3A4TSHRCYP1A2OPRL1 | |
| SCHEMBL6676503 | 0.80 | S1PR1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10398677-B2 | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-09-03 | — | — | US | disclosed |
| US-20180153857-A1 | N-PHENYL-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-07 | — | — | US | disclosed |
| US-9895349-B2 | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND US (IE) | 2018-02-20 | — | — | US | disclosed |
| EP-2981536-B1 | N-PHENYL-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2017-06-14 | — | — | EP | disclosed |
| US-20160051512-A1 | N-PHENYL-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-02-25 | — | — | US | disclosed |
| EP-2981536-A1 | N-PHENYL-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2016-02-10 | — | — | EP | disclosed |
| WO-2014161888-A1 | N-PHENYL-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-10-09 | — | — | WO | disclosed |
| EP-2780039-A2 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | Pfizer Inc (US) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072813-A2 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398677-B2 | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | HCCS, PYGL, XDH | CYP2D6 674/4885CYP3A4 148/4885TSHR 3087/4885 |
| US-20180153857-A1 | N-PHENYL-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | HCCS, PYGL, XDH | CYP2D6 674/4885CYP3A4 148/4885TSHR 3087/4885 |
| US-20160051512-A1 | N-PHENYL-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | HCCS, PYGL, XDH | CYP2D6 674/4885CYP3A4 148/4885TSHR 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.